ADCT vs. GERN

In the year-to-date period, ADCT achieves a -12.06% return, which is significantly higher than GERN's -51.41% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ADCT Sharpe Ratio is -0.55, which is lower than the GERN Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of ADCT and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ADCT nor GERN has paid dividends to shareholders.

The maximum ADCT drawdown since its inception was -99.08%, roughly equal to the maximum GERN drawdown of -98.65%. Use the drawdown chart below to compare losses from any high point for ADCT and GERN. For additional features, visit the drawdowns tool.

The current volatility for ADC Therapeutics SA (ADCT) is 26.53%, while Geron Corporation (GERN) has a volatility of 41.48%. This indicates that ADCT experiences smaller price fluctuations and is considered to be less risky than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between ADC Therapeutics SA and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.